1:16 PM
 | 
Mar 25, 2019
 |  BC Innovations  |  Distillery Therapeutics

IL-17RD or inhibition of ZEB1 to sensitize lung cancer to MEK inhibition

DISEASE CATEGORY: Cancer

INDICATION: Lung cancer

Patient sample, cell culture and mouse studies suggest IL-17RD or blocking ZEB1 via miR-200 expression or HDAC inhibition could sensitize lung cancer to MEK inhibitors. In tumor samples from lung cancer patients, high levels of ZEB1 protein were associated with low levels of MEK signaling. In human and mouse...

Read the full 249 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >